Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 6/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5530466 | 0.94 | PDE5A (0.84) | PDE5A | |
| SCHEMBL1887265 | 0.94 | PDE5A (0.84) | PDE5A | |
| SCHEMBL6407149 | 0.86 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6407365 | 0.85 | PDE5A (0.80) | PDE5A | |
| SCHEMBL6407728 | 0.81 | PDE5A (0.83) | PDE5A | |
| SCHEMBL1891581 | 0.81 | PDE5A (0.83) | PDE5A | |
| SCHEMBL6409809 | 0.80 | PDE5A (0.66) | PDE5A | |
| SCHEMBL14599799 | 0.80 | PDE5A (0.72) | PDE5A | |
| SCHEMBL5527298 | 0.79 | PDE5A (0.56) | PDE5A | |
| SCHEMBL12194946 | 0.78 | PDE5A (0.65) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1851227-A1 | AN EFFICIENT AND STEREOSELECTIVE PROCESS FOR LARGE SCALE SYNTHESIS OF 3-(R)-3- (2,3-DIHYDROBENZOFURAN-5-YL)-1,2,3,4- TETRAHYDROPYRROLO{3,4-B}QUINOLIN-9-ONE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007064316-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070015798-A1 | Efficient and stereoselective process for large scale synthesis of (3R)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-one derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-18 | — | — | US | disclosed |
| WO-2006093719-A1 | AN EFFICIENT AND STEREOSELECTIVE PROCESS FOR LARGE SCALE SYNTHESIS OF 3-(R)-3- (2,3-DIHYDROBENZOFURAN-5-YL)-1,2,3,4- TETRAHYDROPYRROLO{3,4-B}QUINOLIN-9-ONE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015798-A1 | Efficient and stereoselective process for large scale synthesis of (3R)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-one derivatives | PDE5A, PDE3A, PDE3B | PDE5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.